A decision posted to the site of the U.S. District Court for the District of Delaware indicates that the court concludes that Acadia Pharmaceuticals (ACAD) “demonstrated by a preponderance of the evidence that Aurubindo infringes claims 4 and 5 of U.S. Patent No. 11,452,721.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders
- ACADIA Pharmaceuticals Reports Strong Q1 Earnings Growth
- Positive Outlook for ACADIA Pharmaceuticals: Buy Rating Affirmed Amid Strategic Growth Initiatives and Promising Pipeline Developments
- Positive Growth Outlook for ACADIA Pharmaceuticals Driven by Daybue’s Expanding Patient Base and Market Potential
- ACADIA Pharmaceuticals: Promising Growth with Strong Sales Projections and Strategic Advancements